CLINICAL OUTCOMEOF MUSCLE INVASIVE BLADDER CANCER TREATED WITH DEFINITIVE RADIOTHERAPY
Main Article Content
Keywords
Abstract
BACKGROUND:The standard of care treatment approach for Muscle invasive bladder cancer (MIBC) at present is Radical Cystectomy. Organ preservation treatment is offered to patients with MIBC who are either not considered for surgery or patients who refuse surgical management. With this study we wanted to assess the clinical outcome of MIBC patients treated with organ preservation approach.
METODOLOGY:This was a retrospective including MIBC patients treated at our centre with definitive raditherapy/ Chemoradiation.
RESULTS:Details of 18 patients were analysed. Majority of patients in our study were smokers (83%), males (94%) and had T3 as tumor stage. The most common histology was Urothelial carcinoma. Commonest RT schedule used was 60 Gy in 30 fractions (33%). Concurrent chemotherapy was given in six patients (33%). Only three patients (17%) had acute Grade 3 toxicity. Median OS in our study was 45 months. OS at 1 year,2 years and 5 years were 81.4%, 62.8% and 41.9% respectively. Median PFS of patients in this study was 39 months. PFS at 1 year,2 years,4 years were 69.8%, 59.9% and 44.9% respectively.
CONCLUSION: Our study showed that organ preservation approach for MIBC is a well tolerated treatment approach. PFS and OS in our study were slightly lesser compared to available literature. This could be due to the higher proportion of Stage III patients in our study and fewer patients receiving concurrent chemotherapy due to multiple factors like multiple comorbidities and older age. Retrospective nature of study and the lesser number of patients are the limitations of this study.
References
2. Petrovich Z, Jozsef G, Brady LW. Radiotherapy for carcinoma of the bladder: a review. Am J Clin Oncol. 2001;24(1):1–9.
3. Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006 Dec 10;24(35):5536–44.
4. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666–75.
5. Koning CCE, Blank LECM, Koedooder C, van Os RM, van de kar M, Jansen E, et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol Off J Eur Soc Med Oncol. 2012 Nov;23(11):2948–53.
6. Piet AHM, Hulshof MCCM, Pieters BR, Pos FJ, De Reijke TM, Koning CCE. Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer. Strahlenther Onkol. 2008 Jun;184(6):313–8.
7. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002 Jul 1;20(14):3061–71.
8. Chung PWM, Bristow RG, Milosevic MF, Yi Q long, Jewett MAS, Warde PR, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007 Jul;25(4):303–9.
9. Byun SJ, Kim JH, Oh YK, Kim BH. Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J. 2015 Dec 1;33(4):294.
10. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):3801–9.
11. Lutz CT, Livas L, Presnell SR, Sexton M, Wang P. Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity. J Clin Med. 2021 Nov 1;10(21):5163.
12. Halaseh SA, Halaseh S, Alali Y, Ashour ME, Alharayzah MJ. A Review of the Etiology and Epidemiology of Bladder Cancer: All You Need To Know. Cureus. 2022 Jul 27;14(7).
13. Ng KL. The Etiology of Bladder Cancer. Urol Cancers. 2022 Sep 12;23–8.
14. Choong NWW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005 Mar 15;103(6):1172–8.
15. Gofrit ON, Nof R, Meirovitz A, Pode D, Frank S, Katz R, et al. Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study. Urol Oncol Semin Orig Investig. 2015 Jan 1;33(1):19.e1-19.e5.
16. Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, et al. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014;113(6):900–6.
17. Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend? J Urol. 2001;165(1):47–50.
18. SHEN J, LIU X, ZHANG F, HU K, HOU X, LIAN X, et al. Outcome of three-dimensional conformal radiotherapy for 109 patients with bladder cancer. Chinese J Radiat Oncol. 2009;115–9.
19. Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):326–31.
20. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun 1;71(6):952–60.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
NABEEL YAHIYA E K
Assistant Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala,India
ARUN P NARENDRAN
Assistant Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India
Vinin N V
Additional Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India
JONEETHA JONES
Additional Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India
ANJANA P
BSc MRT Intern Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India
AKHIL P SURESH
Assistant Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India
GREESHMA K E
Associate Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala,India
GEETHA MUTTATH
Professor Department of Radiation Oncology Malabar Cancer Centre, Thalassery, Kerala, India